Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model - Test2 - elhamkhani - TriplyDB

Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model

Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model

http://www.wikidata.org/entity/Q28550515

about

Changes in malaria burden and transmission in sentinel sites after the roll-out of long-lasting insecticidal nets in Papua New Guinea The role of early detection and treatment in malaria elimination Mathematical Modelling to Guide Drug Development for Malaria Elimination Implications of Plasmodium vivax Biology for Control, Elimination, and Research Costs and Cost-Effectiveness of Plasmodium vivax Control Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria Plasmodium cynomolgi infections in rhesus macaques display clinical and parasitological features pertinent to modelling vivax malaria pathology and relapse infections Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles.Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum.Synergistic effect of IL-12 and IL-18 induces TIM3 regulation of γδ T cell function and decreases the risk of clinical malaria in children living in Papua New Guinea Malaria control by commodities without practical malariology.Asia-Pacific malaria is singular, pervasive, diverse and invisible An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection.Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand.Declining malaria transmission in rural Amazon: changing epidemiology and challenges to achieve elimination.Anti-malarial seroprevalence assessment during an elimination programme in Chabahar District, south-eastern Iran.Key Knowledge Gaps for Plasmodium vivax Control and Elimination Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.Higher Complexity of Infection and Genetic Diversity of Plasmodium vivax Than Plasmodium falciparum Across All Malaria Transmission Zones of Papua New Guinea.Prevention and control of malaria in pregnancy - new threats, new opportunities?The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea Infectivity of symptomatic and asymptomatic Plasmodium vivax infections to a Southeast Asian vector, Anopheles dirus.The Incidence and Differential Seasonal Patterns of Plasmodium vivax Primary Infections and Relapses in a Cohort of Children in Papua New Guinea Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions.Population-level estimates of the proportion of Plasmodium vivax blood-stage infections attributable to relapses among febrile patients attending Adama Malaria Diagnostic Centre, East Shoa Zone, Oromia, Ethiopia.The Biology of Plasmodium vivax.[Role of primaquine in malaria control and elimination in French-speaking Africa].Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses.Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.Sustained Malaria Control Over an 8-Year Period in Papua New Guinea: The Challenge of Low-Density Asymptomatic Plasmodium Infections.Functional conservation of the AMA1 host-cell invasion ligand between P. falciparum and P. vivax: a novel platform to accelerate vaccine and drug development.malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication.malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.Cost-effectiveness of artemisinin-naphthoquine versus artemether-lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children.malERA: An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication.Insecticide-treated nets and malaria prevalence, Papua New Guinea, 2008-2014.

P2860

Q26315315-04029D1E-859C-4656-8FC1-EFDD9E30D874 Q26740068-70094B20-C8F6-4512-989E-82F71EBBD057 Q28067367-A80F4D80-7B2C-45CD-8D65-E907C6F144B0 Q28355362-37C5DACE-0EAF-4964-968A-80400C82621F Q28355704-E2F3470B-5052-41CC-B953-905F3EDE1E60 Q28553162-C7D6EF58-FB04-4B66-970D-A8D3B4E9EEA5 Q30491343-93A6BEC7-7CFF-412E-90DA-75A8F7E58510 Q30841521-A81AEC5B-ABDF-43C6-9A6F-A8B4348A344F Q33435123-22CC8D7F-3E0E-4BD8-8546-8475AD99EE0F Q33563151-9278AA02-4AA9-4448-8B18-472CBED16ADC Q33636850-DBABA216-4473-4D0B-A20F-B5BEDDBF7988 Q33802385-0C19A4F7-8E08-4E0A-9569-DC28AB0A20ED Q33823424-AD25854A-1615-441A-802D-69DB391ADA7C Q33828552-9CA215D3-EF21-4F8F-AC89-4C222769A70A Q36018397-D43FF71C-9FA3-4828-9029-87880F705DC8 Q36176399-0997B172-BC48-41CA-9CDA-D8406DFB8C48 Q36555051-2A5C53FB-BAF1-4258-8CFD-613DC2732ECC Q36890529-EED1E271-671D-4981-B7C0-61BE6E5C2D62 Q37119475-AD57BBEA-6C1A-4711-A75B-0FCA4CC598C9 Q37546198-F3767CBA-0600-48D3-8A85-D36F5EF8780A Q38603812-8CED0EFA-295A-40FB-B19E-206B52565685 Q39007254-59D97801-E0AE-4F6F-9DFF-0DB7C184DFF3 Q39038490-7DEE9994-4AB5-4CBE-8D7C-67D8E4C038A8 Q39071168-13E8A76A-B04D-468B-AED8-80FCD708F098 Q39135098-C2A42A8B-F412-4667-B4EB-48D6209DFC78 Q39409632-93FA772F-2601-4FDA-868B-4FAFE9D8328A Q39571844-92D87E9A-B614-4471-8CE2-DB4282A67AAE Q40047662-D1956264-5069-429D-BF87-F5857396E93F Q40105373-2E0C20E7-2E23-4615-ABDE-22C24D7792F4 Q40218474-2DEB4737-C356-49C4-A834-E330696947F5 Q40247802-8FB7660A-8B29-4510-8502-A2E93E228703 Q40376176-009D8B33-8E4E-45C1-AED8-0D27748469C4 Q41994105-CCBD563E-EC34-4EA5-A89A-90EF3A97C5A6 Q45972140-B8F2122C-1902-499C-A364-B18ADCDD5402 Q46256154-671DD04B-D321-4807-81FB-E856725B8A54 Q47132201-A844CC66-BEFB-495E-B071-C2132938D0BA Q47134819-953E71B1-E192-4A62-8E31-535CA60EF73C Q47143596-4BECCD67-68F7-4030-8D70-40AFDBD2BB30 Q47157140-6DA1A521-3866-4AA4-BDCA-D94658C536C6 Q47163342-3B46BAFD-EA75-4B13-AD81-06E0DE2CA102

P2860

Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model

http://www.wikidata.org/entity/Q28550515

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Strategies for understanding a ...... d trial and mathematical model

@ast

Strategies for understanding a ...... d trial and mathematical model

@en

Strategies for understanding a ...... d trial and mathematical model

@nl

type

label

Strategies for understanding a ...... d trial and mathematical model

@ast

Strategies for understanding a ...... d trial and mathematical model

@en

Strategies for understanding a ...... d trial and mathematical model

@nl

prefLabel

Strategies for understanding a ...... d trial and mathematical model

@ast

Strategies for understanding a ...... d trial and mathematical model

@en

Strategies for understanding a ...... d trial and mathematical model

@nl

P1433

Q28550515-78C2F6CE-896D-4AC0-8AA9-FA565D3F67D8

P1476

Q28550515-8DAE663E-66D5-4478-B1A2-F6A159AFED01

P2093

Q28550515-1CF80FEB-7537-494D-9760-4723A508467D

Q28550515-1E7B022D-79F7-438A-8EE8-5685BEA3C0C6

Q28550515-24EE6A39-BB4F-41C8-AA86-9259D65DDC77

Q28550515-3EB8F551-6949-433A-99DF-2F37F6648A65

Q28550515-60FB07B3-2E50-431E-82C4-0678662B17F7

Q28550515-7123EBC8-435F-4AFA-826E-946D62594C40

Q28550515-74D4E442-8303-4F2A-A427-63CB0DD42924

Q28550515-85FC98C3-87AA-45B8-808E-D713395AC9FD

Q28550515-AFF0B161-8C4C-437B-9400-00DA1020465D

Q28550515-C9C42A31-C4D3-46BB-A3F3-34BE9F8E56AA

P2860

Q28550515-0167E916-7FF7-4D5C-BE2D-D74E399EF3F7

Q28550515-054BE79F-33AF-4D79-8B11-36DA8B1EC1F5

Q28550515-08C162D0-9E7B-482D-AB08-B2394ADEB911

Q28550515-09BFD90B-ABFD-4696-920C-A67C3BB85C75

Q28550515-102ACD7D-EAAD-4D91-8083-142CC656693F

Q28550515-14C5BE8C-2D52-427A-A7DE-9042395AF268

Q28550515-14F0C2DE-D13F-4625-A819-8DB3CBA5EA08

Q28550515-1A8589FC-720E-47E1-B56D-F4A739BC8223

Q28550515-22D26D42-A657-472F-B414-4CFEC1C05CF2

Q28550515-2340D3BD-B27A-4751-A7D1-DD1D11AC12E8

P304

Q28550515-4C06AB06-3B87-4A4A-9E30-927C0E568667

P31

Q28550515-CA4ED624-6773-45A4-AB5E-0A8FF31D6181

P3181

Q28550515-36662172-A6A0-4500-9EDF-2E0E90D0A862

P356

Q28550515-98BCB8B0-870F-463A-B361-03C4E4A7D93F

P407

Q28550515-118C6216-9989-4059-A105-8A79CA3BE220

P433

Q28550515-6846A65E-EE46-4064-BAF7-762579C4A054

P478

Q28550515-D85B8379-6DA6-4CE2-945A-5591AEA07DDA

P50

Q28550515-018EE7E3-EA52-486F-93AD-8C691A72C6C5

Q28550515-3220A968-8E6A-49ED-B8E9-590AB4C9B99E

Q28550515-56F3AF30-3704-44B5-BA97-E857C865FA99

Q28550515-6F74EA82-BDED-4791-A26C-2E6FF0DF3BBC

Q28550515-90202CCF-93B7-44C4-BAA5-D326B4EFB18F

Q28550515-B268C6CA-AEFC-4D56-B8C6-BBBF53A67BEF

Q28550515-C0CECF6B-48B9-4363-8657-DEF98AC7F6F1

P577

Q28550515-7B9C4CE8-C816-4B72-9885-406321F187E9

P5875

Q28550515-02709087-70F8-4D8E-B507-67FCCBFCA83C

P698

Q28550515-56AC2A67-81D1-4086-8FE8-2A0D1C8B7D2E

P921

Q28550515-6D28AC7B-AF43-46CA-865A-C9DD05015CD8

Q28550515-C297A420-81D3-4203-913F-648BDBA20CC8

Q28550515-D3A48F26-E91F-4D7E-9201-C96E18B41E51

P932

Q28550515-5BCCEA48-B37A-4340-B664-8D679591E9AC

P3181

P356

JOURNAL.PMED.1001891

P1433

P1476

Strategies for understanding a ...... d trial and mathematical model

@en

P2093

Andreea Waltmann

http://www.w3.org/2001/XMLSchema#string

Benson Kinboro

http://www.w3.org/2001/XMLSchema#string

Connie S N Li Wai Suen

http://www.w3.org/2001/XMLSchema#string

Inoni Betuela

http://www.w3.org/2001/XMLSchema#string

Jessica Brewster

http://www.w3.org/2001/XMLSchema#string

Leanne J Robinson

http://www.w3.org/2001/XMLSchema#string

Lina Lorry

http://www.w3.org/2001/XMLSchema#string

Lornah Samol

http://www.w3.org/2001/XMLSchema#string

Mariabeth Silkey

http://www.w3.org/2001/XMLSchema#string

Nandao Tarongka

http://www.w3.org/2001/XMLSchema#string

P2860

Determinants of relapse periodicity in Plasmodium vivax malaria

Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites

Statics and dynamics of malaria infection in Anopheles mosquitoes

Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report

Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies

A research agenda for malaria eradication: drugs

The potential contribution of mass treatment to the control of Plasmodium falciparum malaria

Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial

A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings.

Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial

P304

e1001891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3985

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.1001891

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Mariabeth Silkey

Michael T White

Louis Schofield

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283292767

http://www.w3.org/2001/XMLSchema#string

P698

26505753

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium ovale

Plasmodium vivax

P932

4624431

http://www.w3.org/2001/XMLSchema#string